Advertisement
U.S. markets close in 24 minutes
  • S&P 500

    5,260.31
    +11.82 (+0.23%)
     
  • Dow 30

    39,825.87
    +65.79 (+0.17%)
     
  • Nasdaq

    16,395.63
    -3.89 (-0.02%)
     
  • Russell 2000

    2,123.74
    +9.39 (+0.44%)
     
  • Crude Oil

    83.07
    +1.72 (+2.11%)
     
  • Gold

    2,240.70
    +28.00 (+1.27%)
     
  • Silver

    24.97
    +0.22 (+0.88%)
     
  • EUR/USD

    1.0791
    -0.0039 (-0.36%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2622
    -0.0016 (-0.13%)
     
  • USD/JPY

    151.4020
    +0.1560 (+0.10%)
     
  • Bitcoin USD

    70,874.58
    +2,343.20 (+3.42%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

Caladrius Biosciences to Participate in the Advanced Therapies Congress & Expo 2020

BASKING RIDGE, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, announced today that management will participate in the Advanced Therapies Congress & Expo being held virtually September 8-11, 2020.

Title: Repair of the microcirculation reverses ischemic tissue damage
Presenter: Douglas W. Losordo, M.D., EVP, Global Head of R&D and Chief Medical Officer
Track: Stem Cells and Regenerative Medicine
Date/Time: Wednesday, September 9, 2020 at 12:00 p.m. (BST)

Title: Roundtable discussion: Development of regenerative medicines for cardiovascular indications
Presenter: David J. Mazzo, Ph.D., President and Chief Executive Officer
Track: Stem Cells and Regenerative Medicine
Date/Time: Wednesday, September 9, 2020 at 4:00 p.m. (BST)

Additional information can be found on the conference website.

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease. We are developing a first- in-class cell therapy product that is based on the notion that our body contains finely tuned mechanisms for self-repair. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Company’s current product candidates include CLBS119, a CD34+ cell therapy product candidate for the repair of lung damage found in patients with severe COVID-19 infection who experienced respiratory failure, for which the Company plans to initiate a clinical trial in the coming weeks as well as three developmental treatments for ischemic diseases based on its CD34+ cell therapy platform: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; CLBS16, the subject of a recently completed positive Phase 2 clinical trial in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); and CLBS14, a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”). For more information on the company, please visit www.caladrius.com.

Contact:

Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com

Media:
W2O Group
Christiana Pascale
Phone: +1-212-257-6722
Email: cpascale@w2ogroup.com


Advertisement